Biologics, Therapeutic Monoclonal Antibodies, Antibody Engineering (including, e.g., Fc engineering, humanization, affinity maturation technologies), Phage-display technologies, Follow-on Biologics, Natural Products, Microbiology, Infectious Diseases (primarily bacterial), Antibacterial drugs, Anti-tumor drugs, Pharmaceutical drug discovery and transition to preclinical development, Licensing and partner relationships in biotechnology field.